1. Medtech Insight
  2. >>Business
  3. >>Deals

Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter

A look at M&A and alliance activity across the medical device and in vitro diagnostics industries, July-September 2020

 
• By Deanna Kamienski and Maureen Riordan

Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

M and A diagram, Businessman hand touching M&A (Merger and Acquisition) sign on virtual screen

Featuring 24 completed device M&A transactions, half of which had disclosed values together totaling $17.9bn, the third quarter showed an exponential increase in deal value (and deal volume also notably rose) from Q2’s $159m (for five completed deals; see Exhibit 1). At the top, making up 92% of the Q3 total was Siemens Healthineers AG’s definitive agreement to acquire public radiotherapy developer Varian Medical Systems, Inc.. in an all-cash transaction valued at $16.4bn. ([A#MT142548])

Even without this transaction, the Q3 deal value, at $1.5bn, was still almost 10 times more than the previous quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

More from Business

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.